In a comprehensive study published in ScienceDirect, researchers P. Aghion and P. Howitt delve into the significant role pharmaceutical innovation plays in extending human life expectancy. Their research, titled “The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries,” explores how advancements in medication have contributed to increased longevity across the globe.

The Connection Between Health and Economic Growth

The study begins by highlighting the undeniable link between improvements in health and economic prosperity. With references to works by Nordhaus and Murphy and Topel, the authors underscore that the economic value of increased life expectancy over the past century rivals that of growth in non-health goods and services. This perspective is further supported by the United Nations’ Human Development Index, which considers life expectancy a key component of human development.

The Engine of Growth: Technological Progress

Central to the study is the assertion that technological progress, particularly in the pharmaceutical sector, is a primary driver of economic growth. Through innovations that introduce new products, processes, and markets, the pharmaceutical industry has played a crucial role in enhancing longevity. The study examines the impact of pharmaceutical innovations on life expectancy, focusing on the U.S. and 26 other high-income countries between 2006 and 2018.

Methodology and Findings

The researchers employed two-way fixed-effects analyses to investigate the long-term changes in longevity associated with various diseases. Their findings reveal a strong positive correlation between the mean age at death and life expectancy across countries, suggesting that access to newer pharmaceuticals is linked to increased longevity. Moreover, the study highlights significant international differences in mean age at death from major diseases, which may be attributed to disparities in access to pharmaceutical innovations.

Implications and Conclusions

The study concludes that pharmaceutical innovation has a measurable and positive effect on longevity, both in the U.S. and internationally. By analyzing drug vintage—the year of initial launch of drugs—and its correlation with life expectancy, the researchers provide evidence that newer drugs contribute to extending life. This research not only underscores the value of pharmaceutical innovation in enhancing human health and economic development but also points to the importance of ensuring broad access to these life-extending technologies.

In essence, Aghion and Howitt’s study offers a compelling argument for the critical role of pharmaceutical innovation in driving improvements in health and, by extension, economic growth. It highlights the need for continued investment in biomedical research and development to further extend human life expectancy and improve quality of life worldwide.

66% (6 months) of the 2006-2018 increase in mean age at death of Americans was due to pharmaceutical innovation.

Pharmaceutical innovation has a larger effect on the longevity of people with more education.

73% (1.23 years) of the 2006-2016 increase in mean age at death in 26 countries was due to pharmaceutical innovation.

Estimates of the cost per life-year gained indicate that, overall, pharmaceutical innovation was highly cost-effective.


Leave a Reply